[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE260653T1 - Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen - Google Patents

Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen

Info

Publication number
ATE260653T1
ATE260653T1 AT00943374T AT00943374T ATE260653T1 AT E260653 T1 ATE260653 T1 AT E260653T1 AT 00943374 T AT00943374 T AT 00943374T AT 00943374 T AT00943374 T AT 00943374T AT E260653 T1 ATE260653 T1 AT E260653T1
Authority
AT
Austria
Prior art keywords
naaladase inhibitors
memory disorders
treat anxiety
anxiety
disorders
Prior art date
Application number
AT00943374T
Other languages
English (en)
Inventor
Barbara S Slusher
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Application granted granted Critical
Publication of ATE260653T1 publication Critical patent/ATE260653T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00943374T 1999-07-01 2000-06-30 Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen ATE260653T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/345,782 US6228888B1 (en) 1999-07-01 1999-07-01 Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
PCT/US2000/018260 WO2001001974A2 (en) 1999-07-01 2000-06-30 Naaladase inhibitors in anxiety and memory disorders

Publications (1)

Publication Number Publication Date
ATE260653T1 true ATE260653T1 (de) 2004-03-15

Family

ID=23356457

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00943374T ATE260653T1 (de) 1999-07-01 2000-06-30 Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen

Country Status (9)

Country Link
US (3) US6228888B1 (de)
EP (1) EP1202717B1 (de)
JP (1) JP2003503451A (de)
AT (1) ATE260653T1 (de)
AU (2) AU5785100A (de)
CA (1) CA2378467A1 (de)
DE (1) DE60008753D1 (de)
MX (1) MXPA02000255A (de)
WO (1) WO2001001974A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
EP1093453B1 (de) * 1998-07-06 2005-09-28 Guilford Pharmaceuticals Inc. Naaladase-hemmer anwendbar als pharmazeutische verbindungen und zusammensetzungen
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
AU773915B2 (en) 1999-04-28 2004-06-10 Georgetown University Ligands for metabotropic glutamate receptors
US6528499B1 (en) * 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
WO2001092273A2 (en) * 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
US7220780B2 (en) 2000-05-30 2007-05-22 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating retinal disorders and glaucoma
AU2002357003A1 (en) * 2001-12-28 2003-07-24 Guilford Pharmaceuticals Inc. Indoles as naaladase inhibitors
US20030162694A1 (en) * 2002-02-04 2003-08-28 James Meyerhoff Novel treatment for pathological aggression
DE602004021476D1 (de) * 2003-03-03 2009-07-23 Eisai Corp North America THIOLACTONE ALS NAALADase INHIBITOREN
US20090082305A1 (en) * 2005-03-30 2009-03-26 Kyowa Hakko Kogyo Co., Ltd. Method of improving storage stability of substance
EP2201963B1 (de) 2005-04-05 2016-01-27 Yale University Glutamatmodulationsmittel bei der Behandlung mentaler Störungen
PT2097111E (pt) 2006-11-08 2015-11-03 Molecular Insight Pharm Inc Heterodímeros de ácido glutámico
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
BR112012000210A2 (pt) 2009-06-15 2019-09-24 Molecular Insight Pharm Inc processo para a produção de heterodímeoros de ácido glutâmico.
EP2338892A1 (de) 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostataspezifische Membranantigen-Inhibitoren
WO2012082903A2 (en) * 2010-12-14 2012-06-21 The Johns Hopkins University Treatment of cognitive impairment in a subject with a neurological autoimmune disease
CA2860504A1 (en) 2012-01-06 2013-07-11 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix
KR102187940B1 (ko) 2013-01-14 2020-12-07 몰레큘러 인사이트 파마슈티칼스, 인크. 트리아진계 방사성 의약품 및 방사성 이미지화제

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143908A (en) 1986-11-05 1992-09-01 Merck & Co., Inc. Antibacterial agents and potentiators of carbapenem antibiotics
US4927966A (en) * 1987-06-04 1990-05-22 The Research Foundation Of State University Of New York 2-mercaptomethylglutaric acid derivatives
JPH0474197A (ja) 1990-07-12 1992-03-09 Naoyoshi Suzuki 新規な免疫調整生理活性ペプチド
US6011021A (en) 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5804602A (en) 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US6071965A (en) 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US6384022B1 (en) * 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5902817A (en) * 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US6025345A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
CN1230889A (zh) * 1996-09-27 1999-10-06 吉尔福特药业有限公司 NAALADase组合物和治疗谷氨酸异常及在动物中产生神经元活性的方法
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
ID18382A (id) * 1996-09-27 1998-04-02 Guilford Pharm Inc Komposisi sediaan farmasi dan metoda pengobatan gangguan kompulsif dengan menggunakan inhibitor naaladase
US5981209A (en) 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6028216A (en) * 1997-12-31 2000-02-22 Guilford Pharmaceuticals Inc. Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
US6121252A (en) * 1998-03-30 2000-09-19 Guilford Pharmaceuticals Inc. Phosphinic acid derivatives
EP1093453B1 (de) * 1998-07-06 2005-09-28 Guilford Pharmaceuticals Inc. Naaladase-hemmer anwendbar als pharmazeutische verbindungen und zusammensetzungen

Also Published As

Publication number Publication date
JP2003503451A (ja) 2003-01-28
US20030013687A1 (en) 2003-01-16
MXPA02000255A (es) 2002-06-21
US6376478B1 (en) 2002-04-23
EP1202717A2 (de) 2002-05-08
US6228888B1 (en) 2001-05-08
WO2001001974A2 (en) 2001-01-11
WO2001001974A3 (en) 2002-03-07
AU5785100A (en) 2001-01-22
EP1202717B1 (de) 2004-03-03
CA2378467A1 (en) 2001-01-11
AU2005237108A1 (en) 2005-12-15
DE60008753D1 (de) 2004-04-08

Similar Documents

Publication Publication Date Title
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE554169T1 (de) Smad7-inhibitoren zur behandlung von krankheiten des zns
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE255094T1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
DE60326742D1 (de) Piperazin und piperadin-derivate für die behandlung von neurologischen krankheiten
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE374197T1 (de) Indolderivate zur behandlung von erkrankungen des zentralnervensystems
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60026581D1 (de) Indolderivate zur behandlung von depression und angstzuständen
DE60020833D1 (de) Melatonin zur behandlung von paralysen ausgelöst durch hirnschlag
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties